Saint-Herblain Cedex

• A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma Recruiting
  2024-513077-48-00 5 2024-12-19 O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
• A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Teno … Recruiting
  2023-510422-32-00 5 2024-09-10 Tenosynovial Giant Cell Tumour
• Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting
  2023-509566-38-00 9 2024-08-05 gastroesophageal junction adenocarcinoma
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting
  2023-510275-64-00 9 2023-05-31 Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or ot
• A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizum … Recruiting
  2023-509335-60-00 1 2023-02-23 Advanced solid tumors including (but not limited to), non-small cell l
• A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with ad … Recruiting
  2024-520238-31-01 9 2026-04-20 Advanced Lung Cancer
• A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma Recruiting
  2025-524542-10-00 4 2026-04-14 Endometrial cancer
• Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting
  2024-519208-29-00 4 2026-04-02 Pleural mesothelioma
• Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met … Recruiting
  2025-523224-45-00 10 2026-03-30 Untreated, Unresectable or Metastatic Colorectal Cancer
• A clinical study to find the optimal dose of an investigational treatment called BNT323 when used in combination with another investigationa … Recruiting
  2024-517979-20-00 9 2026-03-04 Advanced Breast Cancer Metastatic Breast Cancer
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• A study to assess the safety, tolerability, pharmacokinetic, pharmacodynamic, immunogenicity and antitumour activity of IPN60300 in adults w … Recruiting
  2025-522139-33-00 7 2026-02-10 Advanced or metastatic solid tumours
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part … Recruiting
  2025-522151-26-00 5 2026-02-06 Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growt
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Metastatic Clear Cell Renal Cell Carcinoma
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Recruiting
  2024-513619-28-00 1 2025-12-11 Clear Cell Renal Cell Carcinoma
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous … Recruiting
  2025-520730-28-00 4 2025-12-08 Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting
  2024-519971-25-00 5 2025-12-03 Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
• ProspectivE phase 0 pilot study, assessing potential prognostic and theranostic interest of 68Ga-PentiXafor PET-CT In metastatic triple neGa … Recruiting
  2024-517658-90-00 3 2025-12-01 triple-negative breast cancer

Showing 49–72 of 230 trials